MARKET

IRON

IRON

Disc Medicine Inc
NASDAQ
62.69
+1.51
+2.47%
Opening 13:48 03/09 EDT
OPEN
62.30
PREV CLOSE
61.18
HIGH
67.15
LOW
61.58
VOLUME
558.69K
TURNOVER
--
52 WEEK HIGH
99.50
52 WEEK LOW
30.82
MARKET CAP
2.39B
P/E (TTM)
-10.4282
1D
5D
1M
3M
1Y
5Y
1D
Disc Medicine Chief Medical Officer William Jacob Savage Reports Common Share Disposal
Reuters · 4d ago
Levi & Korsinsky Probes Disc Medicine Over Bitopertin FDA Setback
Reuters · 4d ago
FDA review process for accelerated approval narrows, less predictable, WSJ says
TipRanks · 6d ago
Disc Medicine Publishes Corporate Presentation on Bitopertin and Iron-Targeting Blood Disease Pipeline
Reuters · 6d ago
Disc Medicine Is Maintained at Overweight by Wells Fargo
Dow Jones · 03/02 16:03
Wells Fargo Maintains Overweight on Disc Medicine, Raises Price Target to $79
Benzinga · 03/02 15:53
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), Butterfly Network (BFLY) and Disc Medicine (IRON)
TipRanks · 03/02 15:40
Wedbush Sticks to Its Buy Rating for Disc Medicine (IRON)
TipRanks · 03/02 14:56
More
About IRON
Disc Medicine, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. The Company's pipeline includes bitopertin for the treatment of erythropoietic porphyrias (Eps), including erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF), and anemia of chronic kidney disease (CKD), and DISC-3405 (formerly MWTX-003) for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, its preclinical programs also include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Bitopertin is the lead product candidate in the Company's heme biosynthesis modulation portfolio. It is developing DISC-3405, a monoclonal antibody against Transmembrane Serine Protease 6 that it licensed from Mabwell Therapeutics, Inc.

Webull offers Disc Medicine Inc stock information, including NASDAQ: IRON real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IRON stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IRON stock methods without spending real money on the virtual paper trading platform.